Medomics Raises Funds to Grow its Sequencing-Based Tests for Mitochondrial Disease

Medomics currently has two next-gen sequencing-based tests on the market — MitoDx and MitoNucleomeDx — both of which are based on Life Technologies' SOLiD system. According to the company, its tests "have produced over $2 million in sales over a few months of limited release in the market."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.